TP53 and myelodysplastic syndrome: For patients with MDS or AML, TP53 mutations probably represent one of the most negative prognostic markers, given their association with low sensitivity to chemotherapy (including venetoclax-based treatments) and substantially worse responses after HSCT [187,188,189,190].